|
Alternative Name
|
CD19 (CD19 Antibody Abstract)
|
|
Background
|
CD19 is a member of the immunoglobulin superfamily and has two Ig like domains. The CD19 Molecule is expressed on 100 % of the peripheral B cells as defined by expression of kappa or lamda light chains. It is expressed on approximately 10 % of normal human peripheral blood cells and approximately 60 % of splenic lymphocytes. It is not expressed on granulocytes, monocytes or T cells as defined by CD3 expression. CD19 defines a pan B antigen which is expressed from the earliest stages of B progenitor development, but is lost on terminal differentiation to plasma cells. It may also be present on some early myeloid progenitors, particularly those of the monoblastic type. The CD19 antigen is expressed on approximately 12 % of peripheral blood lymphocytes. It appears to be expressed on myeloid leukemia cells, particularly those of monocytic lineage. Leukemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen.Synonyms: B-cell marker, B-lymphocyte surface antigen B4, Differentiation antigen CD19, Leu-12
|
|
Gene ID
|
12478
|
|
NCBI Accession
|
NP_033974
|
|
UniProt
|
P25918
|
|
Research Area
|
Stem Cells, Hematopoietic Progenitors, Hematopoietic Stem Cells, Adaptive Immunity, CD Antigens, Surface Receptors of Immune Cells
|
|
Pathways
|
Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway
|
